← All trials
NCT06529445
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 22, 2024
- Primary completion
- Aug 26, 2024
- Completion date
- Aug 26, 2024
- First posted
- Jul 31, 2024
- Last posted
- Aug 29, 2024
- Enrollment
- 84
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangsu vcare pharmaceutical technology co., LTDLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.